

Product Information

Anti-phospho-eIF2B ϵ [pSer⁵³⁹]

Developed in Rabbit, Affinity Isolated Antibody

Product Number **E7655**

Product Description

Anti-phospho-eIF2B ϵ (Eukaryotic Initiation Factor 2B) [pSer⁵³⁹] is developed in rabbit using a synthetic phosphorylated peptide derived from the region of eIF2B ϵ that contains serine 539 as immunogen. The antiserum is affinity purified using epitope-specific affinity chromatography. The antibody is preadsorbed to remove any reactivity toward a non-phosphorylated peptide. Anti-phospho-eIF2B ϵ [pSer⁵³⁹] specifically recognizes eIF2B ϵ phosphorylated at serine 539. The antibody detects human and rat eIF2B ϵ . Other species have not been tested. It has been used in immunoblotting applications.¹

Eukaryotic Initiation Factor 2B (eIF2B) plays a key role by acting as a guanine nucleotide exchange factor in the initiation of mRNA translation in eukaryotic cells. The activity of eIF2B is regulated by a wide array of conditions. Stress inhibits its action, while stimulation of protein synthesis results in activation.

eIF2B ϵ , an 82 kDa subunit of eIF2B, is phosphorylated at serine 539 by glycogen synthase kinase-3 (GSK-3), which leads to inhibition of its guanine nucleotide exchange activity.

eIF2B ϵ , an 82 kDa subunit of eIF2B, is phosphorylated at serine 539 by glycogen synthase kinase-3 (GSK-3), which leads to inhibition of its guanine nucleotide exchange activity.

Reagent

The antibody is supplied as a solution in Dulbecco's phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.3, with 50% glycerol, 1.0 mg/ml BSA (IgG and protease free) and 0.05% sodium azide.

Precautions and Disclaimer

Due to the sodium azide content, a material safety data sheet (MSDS) for this product has been sent to the attention of the safety officer of your institution. Consult the MSDS for information regarding hazards and safe handling practices.

Storage/Stability

Store at -20 °C. Due to the presence of 50% glycerol the antibody will remain in solution. For extended storage, centrifuge the vial briefly before opening and prepare working aliquots. The antibody is stable for at least six months when stored appropriately. Working dilutions should be discarded if not used within 12 hours. The antibody is stable for at least 12 months when stored appropriately.

Product Profile

The supplied reagent is sufficient for 10 blots.

A recommended working concentration of 0.1 to 1.0 μ g/mL is determined by immunoblotting using recombinant eIF2B ϵ treated with GSK-3 β and lambda (λ) phosphatase, CHO-T cells transfected with human insulin receptor (IR) +/- insulin.

Note: In order to obtain best results in different techniques and preparations we recommend determining optimal working concentration by titration test.

Results

Peptide Competition

1. Recombinant eIF-2B ϵ treated with lambda phosphatase λ , (lane 1) or treated with GSK-3 β (lanes 2-5) and added to background extracts were resolved by SDS-PAGE on a 10% Tris-glycine gel and transferred to PVDF.
2. Membranes were blocked with a 5% BSA-TBST buffer overnight at 4 °C.
3. After blocking, membranes were preincubated with different peptides as follow:

Lanes 1 and 2	no peptide
Lane 3	non-phosphorylated peptide corresponding to the immunogen
Lane 4	a generic phosphoserine containing peptide
Lane 5	immunogen

4. All lanes were incubated with 0.50 µg/mL eIF-2Bε [pSer⁵³⁹] antibody for two hours at room temperature in a 3% BSA-TBST buffer.
5. After washing, membranes were incubated with goat F(ab')₂ anti-rabbit IgG alkaline phosphatase and signals were detected.

The data in Figure 1 shows that only the peptide corresponding to eIF-2Bε [pSer⁵³⁹] blocks the antibody signal, demonstrating the specificity of the antibody




Figure 1 Peptide Competition

References

1. Vary, T.C., et al. Phosphorylation of eukaryotic initiation factor eIF2B epsilon in skeletal muscle during sepsis. *Am. J. Physiol.- Endocrinology and Metabolism*, **283**, E1032-E1039 (2002).
2. Wang, X., et al. Eukaryotic initiation factor 2B: identification of multiple phosphorylation sites in the epsilon-subunit and their functions in vivo. *EMBO J.* 20(16):4349-4359 (2001).
3. Woods, Y.L., et al. The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase. *Biochem. J.*, **355**, 609-615 (2001).
4. Kleijn, M., and C.G. Proud The activation of eukaryotic initiation factor (eIF)2B by growth factors in PC12 cells requires MEK/ERK signalling. *FEBS Lett.*, **476**, 262-265 (2000).
5. Jefferson, L.S., et al. Glycogen synthase kinase-3 is the predominant insulin-regulated eukaryotic initiation factor 2B kinase in skeletal muscle. *Int. J. Biochem., Cell. Biol.* **31**, 191-200 (1999).

AH/JK 5/23/2004

Sigma brand products are sold through Sigma-Aldrich, Inc.

Sigma-Aldrich, Inc. warrants that its products conform to the information contained in this and other Sigma-Aldrich publications. Purchaser must determine the suitability of the product(s) for their particular use. Additional terms and conditions may apply. Please see reverse side of the invoice or packing slip.